All News

RheumNow Podcast square

I Can't Treat Ugly (9.20.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Read Article
40 postmenopausal F Rx w/ Blackcurrant (BC) vs PBO. @6 mos BC lowered IL-1β (P .056) & RANKL (P .052) & BMD inversely correlated w/ RANKL change. BC bone protective may also be through enhancing gut microbial balance https://t.co/wy9VR3fwvJ https://t.co/cRCjSb5XDQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective Taiwan's Health claims: studied 6408 RA pts, half HCQ users vs non-users. No higher risk of osteoporosis in HCQ users vs non-users (aHR=0.99; 95% CI: 0.82–1.196). Why study this? HCQ may suppress both bone formation/resorption https://t.co/xShLXMElnH https://t.co/lkvihaYuAd

Links:

Dr. John Cush RheumNow ( View Tweet)
Fracture.spine_.op_.jpg (keep)

Conservative Treatment of Acute Vertebral Fractures

d Jack Cush, MD

A network meta-analysis of pain outcomes in patients with acute osteoporotic vertebral compression fractures (VCFs) showed short-term success with calcitonin and NSAIDs in decreasing pain during activity, but long-term benefits were superior for teriparatide compared to bisphosphonates.

Read Article
A Family History of Arthritis? Using data from the population based All of Us Research Program, a self reported history of arthritis and related conditions was associated with an increased risk for arthritis, osteoporosis, and carpal tunnel syndrome. https://t.co/SApbPLHquQ https://t.co/hOamnYyRoz

Links:

Dr. John Cush RheumNow ( View Tweet)
pedigree.genetics.family.history

A Family History of Arthritis?

d Jack Cush, MD

Using data from the population based All of Us (AoU) Research Program, a self reported history of arthritis and related conditions was associated with an increased risk for arthritis, osteoporosis, and carpal tunnel syndrome.

Read Article
bone%20dense.jpg (keep)

Romosozumab vs. Teriparatide in Postmenopausal Osteoporosis

d Jack Cush, MD

The effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) were compared in a clinical setting, and ROMO showed greater increases in BMD than TPTD after 12 months of therapy, along with a higher completion rate.

Read Article
RheumNow Podcast square

Lead with Lupus (8.2.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com - leading with lupus because everyone wants to know about lupus!

Read Article
knee.calcinosis.inflammation

Frequency and Features of CPPD

d Jack Cush, MD

An international cohort study of patients with calcium pyrophosphate deposition (CPPD) disease, i.e., recurrent acute CPP crystal arthritis, chronic CPP crystal inflammatory arthritis, and crowned dens syndrome (CDS) identifies both acute and chronic inflammatory phenotypes, each with distinctive clinical and imaging diagnostic features.

Read Article
Elder adult Cohort study of 2413 women & 792 men w/ hip BMD-defined osteoporosis based on CT scans, shows 30% of women & 34% of men had hip Fx. Rx w/ alendronate (34%F; 24% M) signif lowered Fx rates (aOR 0.26 and 0.21, respectively) = no sex difference https://t.co/briuZAYVKx https://t.co/xrZ12TmMvM

Links:

Dr. John Cush RheumNow ( View Tweet)
Most read at Annals: Pharmacologic Treatment of Primary #Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From @ACPIMPhysicians https://t.co/wMg63aG4rB https://t.co/ZDKdHkH0fh

Links:

Annals of Int Med AnnalsofIM ( View Tweet)
Most read at Annals: Pharmacologic Treatment of Primary #Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From @ACPIMPhysicians https://t.co/wMg63aG4rB https://t.co/ZDKdHkH0fh

Links:

Annals of Int Med AnnalsofIM ( View Tweet)
RheumNow Podcast square

Pollution and Autoimmunity (7.12.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
MRI.kneepain.jpg

ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update

d Jack Cush, MD

EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).

Read Article
RT @drminidey OP0165- incidence & risk factors of D2T RA in an early RA cohort Factors assoc with D2T RA: 🩸 Seropositivity 🦴 Erosions 📈 Disease activity 📊 D2T pts have higher steroid doses & more commonly develop iatrogenic-related #comorbidities, e.g. osteoporosis

Dr. John Cush RheumNow ( View Tweet)

Late “Breaking”: Reducing Osteoporotic Fractures in Postmenopausal Women Dr. Janet Pope discusses abstract POS0583 presented at Eular 2024 in Vienna, Austria. https://t.co/HIXV4EUkJb https://t.co/p38e6pzAvC

Links:

Dr. John Cush RheumNow ( View Tweet)
When would I use #Aclasta vs #Prolia since #denosumab has LESS #fractures ▶️younger women with #osteoporosis requiring Rx due to long safety ▶️less wearing off when stopping it ▶️noncompliant Pts as prolia reverses effect when dose is missed @RheumNow #EULAR2024 @eular_org https://t.co/0RTGx0sCTd

Links:

Janet Pope Janetbirdope ( View Tweet)

What is better for #Rx of #osteoporosis? #Denosumab or ##Zoledronic acid? #Prolia compared to #Aclasta Giant admin US data of 125,000 Rx niaive women with #OP ▶️Prolia has LESS fractures! POS0583 #EULAR2024 @eular_org @RheumNow https://t.co/eo1ny2VIRf

Links:

Janet Pope Janetbirdope ( View Tweet)
Check point inhibitors may cause bone loss and fractures. Lems W #EULAR2024 @RheumNow https://t.co/rf1AU60Eah

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Stop,pills,water

Can we withdraw treatment in post-menopausal osteoporosis?

d EurekAlert!

Analysis of French claims data, found over half of women initiating oral bisphosphonates (BP) between 2015 and 2020 discontinued treatment for at least one year, which was associated with a 12% increase in fracture risk.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×